Your session is about to expire
← Back to Search
Monoclonal Antibodies
Brodalumab for Hidradenitis Suppurativa
Phase < 1
Waitlist Available
Led By Yael Renert-Yuval, MD
Research Sponsored by Rockefeller University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Study Summary
This study is evaluating whether Brodalumab is safe and effective for treating hidradenitis suppurativa.
Eligible Conditions
- Hidradenitis Suppurativa
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Interleukin-17 receptor A (IL-17RA) saturation during brodalumab administration at week 12 vs baseline
Secondary outcome measures
Change in levels of IL-17A, IL-17C, IL-17, CXCL1, and CXCL8
Correlate IL-17R saturation (measured by the frequencies of immune cells positive to IL-17RA by flow cytometry) with clinical measures, such as pain or the Hidradenitis Suppurativa Severity Score System (IHS4)
Side effects data
From 2019 Phase 4 trial • 210 Patients • NCT0333183534%
Viral upper respiratory tract infection
13%
Headache
9%
Arthralgia
8%
Overdose
6%
Back pain
6%
Nausea
6%
Oropharyngeal pain
6%
Pruritus
5%
Fatigue
5%
Depressive symptom
4%
Diarrhoea
2%
Abdominal pain upper
2%
Abdominal pain
2%
Lymphopenia
1%
Reactive gastropathy
1%
Pancreatic carcinoma metastatic
1%
Stasis dermatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Brodalumab 210 mg
Fumaric Acid Ester
Trial Design
1Treatment groups
Experimental Treatment
Group I: Brodalumab treated moderate-to-severe HS patientsExperimental Treatment1 Intervention
Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brodalumab
FDA approved
Find a Location
Who is running the clinical trial?
Rockefeller UniversityLead Sponsor
158 Previous Clinical Trials
16,353 Total Patients Enrolled
3 Trials studying Hidradenitis Suppurativa
10 Patients Enrolled for Hidradenitis Suppurativa
Yael Renert-Yuval, MDPrincipal Investigator - The Rockefeller University
Rockefeller University
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger